Epigenomics continues to execute on the commercial front. The US is now the main market for Epi proColon, the only FDA-approved, blood-based colorectal cancer screening test. Epi proColon US sales account for c 60% of total 9M16 revenues of €0.9m, 83% up y-o-y. The remainder come from Europe and other countries. Epigenomics recently raised c €5m in a private placement. It has five convertible notes, which mature by year-end 2016 and could raise an additional €2.6m, providing fu
11 Nov 2016
Q316 results and business update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q316 results and business update
- Published:
11 Nov 2016 -
Author:
Juan Pedro Serrate -
Pages:
2
Epigenomics continues to execute on the commercial front. The US is now the main market for Epi proColon, the only FDA-approved, blood-based colorectal cancer screening test. Epi proColon US sales account for c 60% of total 9M16 revenues of €0.9m, 83% up y-o-y. The remainder come from Europe and other countries. Epigenomics recently raised c €5m in a private placement. It has five convertible notes, which mature by year-end 2016 and could raise an additional €2.6m, providing fu